NCT06871410 2026-03-24
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Recruiting
Clinical Trials
10 trialsNCT06930352 2026-03-13
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT02782546 2025-12-24
Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
Phase 2 Active not recruiting
NCT06572631 2025-05-25
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
City of Hope Medical Center
Phase 1 Withdrawn
NCT01898793 2024-01-17
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
Phase 1/2 Terminated
NCT02639559 2023-11-07
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
Phase 2 Completed
NCT04354025 2023-04-04
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
Washington University School of Medicine
Phase 2 Withdrawn
NCT03126864 2019-11-04
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00363467 2017-03-23
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT02842112 2016-07-25
Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia
Hospices Civils de Lyon
Completed